What's in Lung Biotechnology PBC's pipeline?

Lung Biotechnology PBC has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Lung Biotechnology PBC's portfolio?

Top competitors by shared drug class: AOP Orphan Pharmaceuticals AG, Civi Biopharma, Inc., GlaxoSmithKline, Liquidia Technologies, Inc., Ludwig-Maximilians - University of Munich.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lung-biotechnology-pbc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lung Biotechnology PBC — Portfolio Competitive Intelligence Brief

Lung Biotechnology PBC pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AOP Orphan Pharmaceuticals AG · 1 shared drug class
Civi Biopharma, Inc. · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Liquidia Technologies, Inc. · 1 shared drug class
Ludwig-Maximilians - University of Munich · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lung Biotechnology PBC:

Cite this brief

Drug Landscape (2026). Lung Biotechnology PBC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lung-biotechnology-pbc. Accessed 2026-05-16.